Keeps Biopharma Inc. (KOSDAQ:256940)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,640.00
+120.00 (2.17%)
At close: Sep 11, 2026

Keeps Biopharma Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-12,389-9,7851,1133,930-11,375-15,317
Depreciation & Amortization
5,4384,4882,5821,442993.33812.4
Loss (Gain) From Sale of Assets
-7,05146.89-24.1577.46-52.48-19.15
Asset Writedown & Restructuring Costs
--383.84---
Loss (Gain) From Sale of Investments
2,3642,633-847.49-1,077177.952,519
Loss (Gain) on Equity Investments
1,9341,7201,609-4,9303,9983,081
Stock-Based Compensation
---269.1509.971,458
Provision & Write-off of Bad Debts
-1,018-923.58-1,34370.84912.842,926
Other Operating Activities
14,7804,4965,2585,255565.12-2,073
Change in Accounts Receivable
-4,168-3,920-963.41-622.46561.76-1,447
Change in Inventory
-8,089-11,178-4,816-696.770.6-1,997
Change in Accounts Payable
185.91-2,010-1,0901,224-138.22611.5
Change in Other Net Operating Assets
-3,562-488.162,945-4,9992,9801,066
Operating Cash Flow
-11,577-14,9214,808-57.13-866.26-8,380
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-32,191-31,933-6,596-990.97-95.85-90.75
Sale of Property, Plant & Equipment
1,7071,62127.1824.1830.3138.3
Cash Acquisitions
-9,726-5,339-17,812-26,610--
Sale (Purchase) of Intangibles
-1,036-2,864-104.49-79.79-33.96-32.2
Investment in Securities
-2,132137.99100.66682.22-3,199-11,484
Other Investing Activities
15,036-446.73456.64992.3-4,784-88.42
Investing Cash Flow
-29,815-40,297-22,275-27,591-9,427-14,276

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-4,50150019,000-3,000
Long-Term Debt Issued
-59,09312,0123,000-32,000
Total Debt Issued
29,21563,59412,51222,000-35,000
Short-Term Debt Repaid
--790.02-6,000-13,000--7,000
Long-Term Debt Repaid
--555.05-6,234-248.51-3,327-330.69
Total Debt Repaid
-10,482-1,345-12,233-13,249-3,327-7,331
Net Debt Issued (Repaid)
18,73462,249278.158,751-3,32727,669
Issuance of Common Stock
-1,199--353.55398.18
Other Financing Activities
-4,829-4,91031,649-600-298-35.68
Financing Cash Flow
13,90558,53731,9278,151-3,27228,032

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
58.47-53.2210.67-21.75-6.82673.45
Net Cash Flow
-27,4293,26614,671-19,519-13,5726,049

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-43,768-46,854-1,787-1,048-962.12-8,471
Free Cash Flow Growth
------
Free Cash Flow Margin
-19.85%-27.54%-1.40%-1.14%-6.58%-198.82%
Free Cash Flow Per Share
-2190.02-2388.42-94.70-55.71-51.34-489.19
Levered Free Cash Flow
-43,811-61,11821,450-12,42323.1-9,364
Unlevered Free Cash Flow
-39,333-56,64023,782-11,154607.29-8,308

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
1,9981,8141,3261,360-79.71
Cash Income Tax Paid
782.942,27913.8514.57137.2843.29
Change in Working Capital
-15,634-17,596-3,924-5,0953,405-1,766